City Therapeutics Inc. CTY · News

website

City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference ...

Price18.67

Market Cap965.63 M

Float11.11 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

FEATURED

Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (NASDAQ:CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced

Summary

Nov 4, 2026, 9:01 AM ·Globe Newswire

RECENT

City Therapeutics to Present at Upcoming November Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (NASDAQ:CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced

Nov 3, 2026, 8:00 AM ·Globe Newswire

City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (NASDAQ:CTY) ("City" or "City Therapeutics"), a clinical-stage biotechnology company developing the next generation of RNA

Oct 19, 2026, 4:01 PM ·Globe Newswire

City Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (NASDAQ:CTY) ("City" or "City Therapeutics"), a clinical-stage biotechnology company developing the next generation of RNA

Oct 15, 2026, 10:37 PM ·Globe Newswire